These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect. Castaman G, Federici AB, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F. J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565 [Abstract] [Full Text] [Related]
28. 1-Deamino-8-D-arginine-vasopressin--an alternative in the management of mild haemophilia A and von Willebrand's disease. Niessner H, Korninger C. Wien Klin Wochenschr; 1983 Nov 11; 95(21):753-7. PubMed ID: 6424339 [Abstract] [Full Text] [Related]
29. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease. Casonato A, Pontara E, Dannhaeuser D, Bertomoro A, Sartori MT, Zerbinati P, Girolami A. Blood Coagul Fibrinolysis; 1994 Dec 11; 5(6):959-64. PubMed ID: 7893933 [Abstract] [Full Text] [Related]
30. Desmopressin (DDAVP) in bleeding disorders of childhood. Sutor AH. Semin Thromb Hemost; 1998 Dec 11; 24(6):555-66. PubMed ID: 10066151 [Abstract] [Full Text] [Related]
31. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? Brown SA, Eldridge A, Collins PW, Bowen DJ. J Thromb Haemost; 2003 Aug 11; 1(8):1714-7. PubMed ID: 12911582 [Abstract] [Full Text] [Related]
32. Response to low-dose desmopressin by a subcutaneous route in children with type 1 von Willebrand disease. Akin M. Hematology; 2013 Mar 11; 18(2):115-8. PubMed ID: 23321055 [Abstract] [Full Text] [Related]
33. Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A. Ragni MV, Novelli EM, Murshed A, Merricks EP, Kloos MT, Nichols TC. Thromb Haemost; 2013 Feb 11; 109(2):248-54. PubMed ID: 23238591 [Abstract] [Full Text] [Related]
34. Assessment and validation of a defined fluid restriction protocol in the use of subcutaneous desmopressin for children with inherited bleeding disorders. Mason JA, Robertson JD, McCosker J, Williams BA, Brown SA. Haemophilia; 2016 Sep 11; 22(5):700-5. PubMed ID: 27385253 [Abstract] [Full Text] [Related]
36. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1. Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HH. Acta Haematol; 2009 Sep 11; 121(2-3):85-97. PubMed ID: 19506353 [Abstract] [Full Text] [Related]
37. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor. Casonato A, Dannhauser D, Pontara E, Bertomoro A, Orazi B, Santarossa L, Zerbinati P, Girolami A. Blood Coagul Fibrinolysis; 1996 Jul 11; 7(5):549-53. PubMed ID: 8874865 [Abstract] [Full Text] [Related]
38. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Ragni MV, Jankowitz RC, Chapman HL, Merricks EP, Kloos MT, Dillow AM, Nichols TC. Haemophilia; 2008 Sep 11; 14(5):968-77. PubMed ID: 18680527 [Abstract] [Full Text] [Related]
39. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Lethagen S, Harris AS, Nilsson IM. Blut; 1990 Mar 11; 60(3):187-91. PubMed ID: 2107887 [Abstract] [Full Text] [Related]